dr. lampson on safety and efficacy of acalabrutinib, venetoclax, and obinutuzumab in cll
Published 4 years ago • 271 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
3:53
the safety and efficacy of venetoclax/obinutuzumab combo in cll
-
3:18
benjamin lampson: acalabrutinib combo leads to deep, durable responses in frontline cll
-
8:16
venetoclax and obinutuzumab in cll
-
12:05
venetoclax combinations, safety and efficacy
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
3:52
dr. flinn on venetoclax and obinutuzumab in cll
-
6:20
acalabrutinib and venetoclax vs. venetoclax and obinutuzumab for cll - dr. matt davids
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
9:15
obinutuzumab venetoclax for frontline cll
-
1:09
majic: venetoclax with acalabrutinib or obinutuzumab in cll
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
1:01
dr. abedin on the role of venetoclax plus obinutuzumab in cll
-
1:25
dr. rogers discusses obinutuzumab, ibrutinib, and venetoclax combination in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
0:52
42-month follow-up data of acalabrutinib monotherapy in r/r cll
-
1:13
dr. jones on the safety of venetoclax in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
5:21
acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with cll
-
1:35
the safety and efficacy of tirabrutinib and entospletinib with or without obinutuzumab in r/r cll